| 2026-08-06 | 10-Q | 10.2 | 2019 Employee Stock Purchase Plan, as amended, and form of agreement thereunder |
|---|
| 2026-02-25 | 10-K | 10.18 | Separation Agreement, dated December 22, 2025, by and between Alector, Inc. and Saraswati (Sara) Kenkare-Mitra, Ph.D. |
|---|
| 2025-08-07 | 10-Q | 10.1 | Outside Director Compensation Policy |
|---|
| 2025-05-08 | 10-Q | 10.1 | Outside Director Compensation Policy |
|---|
| 2025-02-26 | 10-K | 10.22 | First Amendment to Loan and Security Agreement, dated December 12, 2024, by and among Alector Inc., Alector LLC, certain banks and other financial institutions, and Hercules Capital, Inc., as administrative agent and collateral agent |
|---|
| 2025-02-26 | 10-K | 10.21 | Loan and Security Agreement, dated as of November 14, 2024, among the Registrant and Alector LLC, as co-borrowers, the banks and financial institutions from time to time party thereto, and Hercules Capital, Inc., as administrative agent and collateral agent |
|---|
| 2024-05-08 | 10-Q | 10.2 | Outside Director Compensation Policy |
|---|
| 2024-05-08 | 10-Q | 10.1 | Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated March 11, 2024. |
|---|
| 2024-02-27 | 10-K | 10.11 | Outside Director Compensation Policy. |
|---|
| 2024-02-27 | 10-K | 10.4 | 2019 Employee Stock Purchase Plan and form of agreement thereunder. |
|---|
| 2024-02-27 | 10-K | 10.3 | 2019 Equity Incentive Plan and forms of agreements thereunder. |
|---|
| 2023-08-03 | 10-Q | 10.1 | Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated May 19, 2023. |
|---|
| 2023-05-04 | 10-Q | 10.1 | Amendment Number One to Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology Ltd., effective February 13, 2023. |
|---|
| 2023-02-28 | 10-K | 10.18 | Offer Letter dated November 30, 2021 by and between Alector, LLC and Saraswati (Sara) Kenkare-Mitra, Ph.D. |
|---|
| 2023-02-28 | 10-K | 10.11 | Outside Director Compensation Policy. |
|---|
| 2022-09-26 | 8-K | 10.1 | 2022 Inducement Equity Incentive Plan, as amended, and related forms of stock option and restricted stock unit agreements. |
|---|
| 2022-03-29 | 8-K | 10.1 | Offer Letter between Alector, Inc. and Gary Romano, Ph.D., M.D. |
|---|
| 2022-02-24 | 10-K | 10.19 | Offer Letter dated February 7, 2022 by and between Alector, LLC and Marc Grasso, MD |
|---|
| 2022-02-24 | 10-K | 10.18 | Offer Letter dated November 30, 2021 by and between Alector, Inc. and Saraswati (Sara) Kenkare-Mitra, Ph.D. |
|---|
| 2022-02-07 | 8-K | 10.1 | Offer Letter dated February 4, 2022 by and between Alector, Inc.and Marc Grasso, MD |
|---|
| 2022-01-03 | 8-K | 10.1 | Separation Agreement and Release of Claims, dated December 31, 2021, by and between Shehnaaz Suliman and Alector, LLC. |
|---|
| 2022-01-03 | 8-K | 10.1 | 2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements. |
|---|
| 2021-11-04 | 10-Q | 10.3 | Confidential Consulting Agreement, effective September 3, 2021, by and between FLG Partners and Alector, LLC. |
|---|
| 2021-09-07 | 8-K | 10.2 | Letter Agreement, dated September 7, 2021, by and between Robert Paul and Alector, LLC |
|---|
| 2021-09-07 | 8-K | 10.1 | Transition Agreement, dated September 7, 2021, by and between Shehnaaz Suliman and Alector, LLC |
|---|
| 2021-08-03 | 10-Q | 10.19 | Collaboration and License Agreement, dated July 1, 2021, by and between Glaxo Wellcome UK Limited and Alector, Inc. |
|---|
| 2021-03-26 | 8-K | 10.1 | Retention Letter Agreement, dated March 23, 2021, among Mr. Calvin Yu and Alector, Inc. |
|---|
| 2020-03-24 | 10-K | 10.11 | Outside Director Compensation Policy. |
|---|
| 2019-11-12 | 10-Q | 10.17 | 2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August 16, 2019. |
|---|